Skip to main content

Table 4 Predicted ADMET properties of the selected compounds

From: In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions

SN

GI absorption

BBB permeant

Bioavailability score

CYP-substrate/inhibitor

5

Low

No

0.55

3A4

1A2

2C19

2C9

2D6

9

Low

No

0.55

Yes

Yes

Yes

No

Yes

10

Low

No

0.55

Yes

Yes

Yes

No

Yes

11

Low

No

0.55

Yes

Yes

Yes

No

Yes

Vem.

Low

No

0.55

Yes

Yes

Yes

No

Yes

  1. GI gastrointestinal system, BBB blood–brain barrier, CYP cytochrome P